The levonorgestrel-releasing intrauterine system (LNG-IUS; Mirena) was first licensed in the UK for contraception in 1995. But it soon became evident that it had other clinical advantages and the LNG-IUS is now also available for the prevention of endometrial hyperplasia in women who are taking oestrogen as part of hormone replacement therapy (HRT).
